Tiziana Life Sciences Doses First Alzheimer's Patient
Ticker: TLSA · Form: 6-K · Filed: Dec 17, 2024 · CIK: 1723069
Sentiment: neutral
Topics: clinical-trial, alzheimers, drug-development
TL;DR
Tiziana Life Sciences dosed first Alzheimer's patient with intranasal foralumab on Dec 17, 2024.
AI Summary
On December 17, 2024, Tiziana Life Sciences LTD announced a significant milestone in its Alzheimer's disease clinical development program. The company successfully dosed the first patient with moderate Alzheimer's disease using intranasal foralumab.
Why It Matters
This marks a crucial step in Tiziana's development of a potential treatment for Alzheimer's disease, a condition affecting millions worldwide.
Risk Assessment
Risk Level: medium — Clinical trial progress is inherently risky, with many potential setbacks in drug development.
Key Players & Entities
- Tiziana Life Sciences LTD (company) — Registrant
- December 17, 2024 (date) — Announcement Date
- foralumab (drug) — Investigational Drug
FAQ
What is the specific indication for the clinical trial involving intranasal foralumab?
The filing states the first patient dosed had moderate Alzheimer's disease.
When was this milestone announced?
The announcement was made on December 17, 2024.
What is the name of the company filing this report?
The company is Tiziana Life Sciences LTD.
What is the form type being filed?
This is a Form 6-K, Report of Foreign Private Issuer.
What is the primary business of Tiziana Life Sciences?
The company is in the Pharmaceutical Preparations industry (SIC code 2834).
Filing Stats: 336 words · 1 min read · ~1 pages · Grade level 13.6 · Accepted 2024-12-17 07:00:28
Filing Documents
- ea0225033-6k_tiziana.htm (6-K) — 14KB
- ea022503301ex99-1_tiziana.htm (EX-99.1) — 15KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- 0001213900-24-109499.txt ( ) — 34KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TIZIANA LIFE SCIENCES LTD Date: December 17, 2024 By: /s/ Keeren Shah Name: Keeren Shah Title: Chief Financial Officer 2 EXHIBIT INDEX Exhibit No. Description 99.1 Tiziana Life Sciences LTD Press Release, dated December 17, 2024 3